Finance

Beta
Lists
QURE:NASDAQ
Uniqure NV
$47.51
-3.24%
(-1.59) 1D
$48.12
+1.28% (+0.61)
After hours
Closed: Jun 26, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for QURE...
Open
$49.23
High
$49.70
Low
$46.17
Mkt. cap
3.23B
Avg. vol.
2.37M
Volume
3.16M
52-wk high
$71.50
52-wk low
$8.73
EPS
-$3.51
Beta
0.98
Shares outstanding
63.07M
No. of employees
221
Open
$49.23
High
$49.70
Low
$46.17
Mkt. cap
3.23B
Avg. vol.
2.37M
Volume
3.16M
52-wk high
$71.50
52-wk low
$8.73
EPS
-$3.51
Beta
0.98
Shares outstanding
63.07M
No. of employees
221
News stories
From sources across the web
Profile
uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies. Wikipedia
About Uniqure NV
CEOMatt Kapusta
Employees221
Founded1998
Headquarters-
SectorBiotechnology
Websiteuniqure.com
Analyst ratings
Based on 11 analysts giving stock ratings to QURE in the past 3 months
Strong buy
Buy
10
Hold
1
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for QURE in the last 3 months.
Highest
Current $47.51
$95.00 (+99.96%)
Average
$63.00 (+32.60%)
Lowest
$37.00 (-22.12%)
Analyst
Recommendation
Action
Price target
Projected
Date
Uy Ear
Mizuho Securities
Buy
Reiterated
$68.00
+43.1%
06/24/2026
Eliana Merle
Barclays
Buy
Upgraded
$65.00
+36.8%
06/22/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
$71.00
+49.4%
06/21/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
$70.00
+47.3%
06/17/2026
Luca Issi
RBC Capital
Buy
Maintained
$65.00
+36.8%
06/18/2026
Salveen Richter
Goldman Sachs
Hold
Reiterated
$46.00
-3.2%
06/17/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
06/17/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Upgraded
-
-
06/17/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$50.00
+5.2%
06/18/2026
Daniil Gataulin
Chardan Capital
Buy
Reiterated
$37.00
-22.1%
05/05/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$95.00
+100%
05/05/2026
Yanan Zhu
Wells Fargo
Buy
Upgraded
$60.00
+26.3%
03/09/2026
Rudy Li
Wolfe Research
Hold
Initiated
-
-
02/23/2026
Sami Corwin
William Blair
Hold
Reiterated
-
-
02/06/2026
Last report
May 5, 2026
Fiscal period
Q1 2026
EPS / Est. (EUR)
-€0.73 / -€0.75
+3.34%beat
Revenue / Est. (EUR)
3.04M / 4.49M
-32.18%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
5.26M
3.70M
5.57M
3.56M
Cost of goods sold
33.78M
32.25M
40.18M
30.73M
Cost of revenue
33.78M
32.25M
40.18M
30.73M
Research and development expenses
-
695.00K
-5.92M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.50M
19.44M
21.61M
20.07M
Operating expense
13.09M
20.67M
15.55M
19.89M
Total operating expenses
46.87M
52.91M
55.73M
50.62M
Operating income
-41.61M
-49.21M
-50.16M
-47.06M
Other non operating income
-
-7.22M
18.13M
3.77M
EBT including unusual items
-37.29M
-71.90M
-41.00M
-53.05M
EBT excluding unusual items
-35.04M
-70.08M
-40.05M
-54.38M
Income tax expense
425.00K
8.63M
-3.92M
488.00K
Effective tax rate
-1.14%
-12.00%
9.55%
-0.92%
Other operating expenses
-412.00K
534.00K
-143.00K
-181.00K
Net income
-37.72M
-80.53M
-37.09M
-53.54M
Net profit margin
-716.82%
-2,175.87%
-666.06%
-1,502.95%
Earnings per share
-
-
-
-
Interest and investment income
3.52M
3.50M
5.81M
5.23M
Interest expense
-15.59M
-16.72M
-14.57M
-14.03M
Net interest expenses
-12.07M
-13.22M
-8.76M
-8.80M
Depreciation and amortization charges
-
-
-
-
EBITDA
-37.98M
-45.58M
-47.19M
-44.10M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of QURE
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer